This product is compounded tesamorelin — a preparation containing the same active ingredient as FDA-approved tesamorelin (Egrifta), made by a licensed compounding pharmacy. Off-label use for body composition and visceral fat reduction. Prescription required.

GHRH Analogue · Compounded

Targeted growth hormone optimization. More precise than sermorelin.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that directly stimulates the pituitary to release growth hormone pulses — working with your body's natural feedback loop rather than replacing it.

FDA-approved as Egrifta for HIV-associated lipodystrophy, tesamorelin is prescribed off-label for visceral fat reduction, body recomposition, and growth hormone optimization. Clinical research demonstrates ~20% reduction in visceral adipose tissue alongside preserved insulin sensitivity and enhanced IGF-1 production.

At Obsidian Genetics, we offer physician-supervised compounded tesamorelin — one flat monthly price, personalized dosing, and ongoing provider support built in.

Prescription required · Free shipping
Tesamorelin
Compounded GHRH analog targeting visceral fat reduction. Daily subcutaneous injection, physician supervised.
Pricing
$

Includes ongoing provider care & support
Compounded medication · Platform access

🛡️100% Online
🩺Board-Certified
📦Fast Shipping
What the Research Shows

The clinical evidence behind tesamorelin.

15+ years of data supporting visceral fat reduction and GH optimization in clinical populations.

~15%
Visceral adipose tissue reduction Falutz et al. 2007 NEJM RCT (n=412) reported 15.2% decrease in visceral adipose tissue with daily 2mg tesamorelin vs. 5.0% increase with placebo at 26 weeks
+81%
Increase in IGF-I levels Same Falutz 2007 NEJM RCT: IGF-I increased 81% in the tesamorelin group vs. decreased 5% in placebo, confirming activation of the GH/IGF-I axis
15+ yrs
Clinical data on safety and efficacy FDA-approved molecule with extensive real-world use
Preserved
Insulin sensitivity maintained Works with body's natural feedback vs. exogenous GH
EGRIFTA / Falutz NEJM 2007 — Falutz J et al., N Engl J Med. 2007;357(23):2359-70; PMID 18057338; randomized placebo-controlled trial of daily 2mg tesamorelin (n=412) in HIV-associated abdominal fat accumulation. 15.2% VAT reduction, 81% IGF-I increase  |  FDA APPROVED — Tesamorelin (Egrifta) approved for HIV-associated lipodystrophy · 15+ years of clinical monitoring

Clinical outcomes cited reflect published research on the tesamorelin molecule in FDA trials and approved indication. Off-label use for body composition and metabolic optimization is prescribed by a licensed provider. Compounded tesamorelin contains the same active ingredient as branded Egrifta but is not FDA-approved and has not undergone independent clinical trials. Individual results vary. Prescription required.

Clinical Applications

Prescribed For

→ Visceral fat reduction Research Supported
→ Body composition optimization Research Supported
→ Growth hormone optimization Research Supported
→ Metabolic health & insulin sensitivity Research Supported
→ Cognitive function & memory Emerging Research
→ Anti-aging & cellular repair Emerging Research
→ Athletic recovery & performance Emerging Research

*Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Off-label use prescribed at provider discretion.

[ Body composition / athletic physique ]
What You Get

A complete program. One flat price.

01

Physician consultation & protocol setup

Licensed provider reviews your health profile, establishes your tesamorelin protocol, and guides initial dosing.

02

Compounded tesamorelin vials

Monthly supply of physician-prescribed tesamorelin vials, compounded by a licensed pharmacy.

03

Supplies & administration kit

Bacteriostatic water, sterile syringes, alcohol pads, and injection guidance — everything needed for safe subcutaneous administration.

04

Ongoing provider support & monitoring

Check-ins, protocol adjustments, lab monitoring guidance, and provider access throughout your treatment.

05

Free, discreet shipping

Fast delivery, confidential packaging — right to your door.

[ Injection administration / lab results / program kit ]
Mechanism

How tesamorelin works.

Step 01
[ GHRH receptor binding illustration ]

Tesamorelin binds GHRH receptors in the anterior pituitary gland, directly triggering endogenous growth hormone pulses.

Step 02
[ IGF-1 production / liver illustration ]

Stimulated GH pulses signal the liver to produce insulin-like growth factor-1 (IGF-1), promoting systemic anabolic effects.

Step 03
[ Visceral fat reduction / muscle protein synthesis ]

IGF-1 and elevated GH promote lipolysis in visceral fat depots, muscle protein synthesis, and cellular repair — while preserving insulin sensitivity.

Important Information

Safety & Considerations

Tesamorelin is a prescription medication prescribed off-label for body composition optimization. Your Obsidian Genetics provider will review your full health history before prescribing.

⚠ Important Safety Information

Do not use tesamorelin if you have active malignancy or a pituitary tumor. Tesamorelin stimulates GH secretion and is contraindicated in patients with proliferative pituitary lesions. Not recommended during pregnancy. If you have a history of pancreatitis, discuss with your provider before starting treatment.

Common side effects: Injection site reactions (mild redness, swelling), fluid retention (mild, typically resolves), transient joint pain. Less common: Carpal tunnel syndrome symptoms (rare at physiologic doses), headache. Important: Tesamorelin works WITH your body's natural feedback loop, unlike exogenous GH — it does not suppress endogenous GH production and preserves insulin sensitivity when used as prescribed.

FREQ—
UENTLY
ASKED

Both are GHRH analogues that stimulate endogenous GH release, but tesamorelin is more potent and longer-acting than sermorelin. Tesamorelin is FDA-approved as Egrifta and has 15+ years of clinical data showing robust visceral fat reduction and GH optimization. Sermorelin has a shorter half-life and requires more frequent dosing. Tesamorelin is considered more targeted and effective for body composition goals.
No — tesamorelin is fundamentally different from exogenous HGH. Tesamorelin stimulates YOUR body to release its own growth hormone naturally. It works WITH your pituitary gland's feedback mechanisms. Exogenous HGH replaces your natural production, potentially suppressing your body's own GH secretion over time. Tesamorelin preserves insulin sensitivity, whereas exogenous GH can reduce it. For most patients seeking GH optimization without disrupting natural feedback, tesamorelin is a more physiologic approach.
Tesamorelin is a peptide administered as a subcutaneous (under-the-skin) injection, typically once daily or as directed by your provider. Your kit includes sterile syringes, bacteriostatic water for reconstitution, and alcohol pads. Your provider will walk you through the injection technique during your initial consultation. Common injection sites are the abdomen, thigh, or upper arm — rotating sites helps prevent irritation.
Timeline varies by individual, but most patients experience: Week 1–2: Protocol established, injection technique mastered. Month 1: GH optimization begins, sleep quality improvements often noted. Month 2–3: Visible body composition changes, visceral fat reduction becomes measurable. Month 4–6: Full body recomposition effect, IGF-1 stabilization, sustained fat loss and muscle preservation. Clinical trials showed ~20% VAT reduction over the study period. Results depend on baseline body composition, diet, activity level, and adherence.
Tesamorelin (Egrifta) has 15+ years of clinical safety data in FDA-approved use for HIV-associated lipodystrophy, with many patients using it continuously. It works WITH your body's natural GH feedback, so it does not cause the long-term suppression risks associated with exogenous HGH. That said, it is off-label for body composition optimization, so ongoing provider monitoring and periodic lab work are important to ensure continued safety and efficacy. Your provider will assess whether continued use is appropriate for your health goals.
Unlike exogenous HGH, which can reduce insulin sensitivity, tesamorelin preserves insulin sensitivity because it works through your body's natural GH feedback loop. Clinical data shows tesamorelin does not negatively impact glucose control. However, if you have diabetes or prediabetes, your provider may recommend periodic glucose monitoring to track any changes. Always disclose your full metabolic health history during your initial consultation.

Important: This product is compounded tesamorelin. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Off-label use for body composition, visceral fat reduction, and growth hormone optimization is prescribed by a licensed healthcare provider at their clinical discretion. Compounded tesamorelin is prepared by a licensed compounding pharmacy and is not FDA-approved as an independent product. Its safety and effectiveness have not been independently verified by the FDA for off-label indications. A licensed Obsidian Genetics physician will evaluate your health history and determine whether this medication is appropriate for you. Prescription required. Individual results vary. Research statistics and clinical outcomes cited reflect published clinical trials of branded tesamorelin (Egrifta) — results with compounded formulations have not been independently verified. Do not use tesamorelin if you have active malignancy or a pituitary tumor. Not recommended during pregnancy. Always disclose all medications, supplements, and health conditions to your provider.